Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)

1. Sun, R.
2. Champiat, S.
3. Dercle, L.
4. Aspeslagh, S.
5. Castanon, E.
6. Limkin, E.J.
7. Baldini, C.
8. Postel-Vinay, S.
9. Hollebecque, A.
10. Massard, C.
11. Ammari, S.
12. Deutsch, E.
13. Soria, J.-C.
14. Marabelle, A.
15. Ferté, C.